Radiotherapy in the treatment of rectal cancer − is it time to move on?
Authors:
P. Ihnát 1; P. Vávra 2; I. Slívová 1; L. Tulinský 2
; I. Penka 1
Authors place of work:
Chirurgická klinika, FN Ostrava
1; Katedra chirurgických oborů, LF Ostravské univerzity
2
Published in the journal:
Rozhl. Chir., 2018, roč. 97, č. 4, s. 156-160.
Category:
Review
Summary
Multidisciplinary treatment approach in accordance with current guidelines represents a gold standard of care for patients with rectal cancer. Radical surgical resection is a fundamental and the only curative treatment modality. Patients with locally advanced rectal cancer (cT3-4N0M0 or anyTN1-2M0) are indicated for neoadjuvant radiotherapy or radiochemotherapy. However, there are many controversies regarding neoadjuvant radiotherapy indications in the available literature. Evidence-based medicine data suggest that neoadjuvant radiotherapy is associated with improved local control of the disease, but has no impact on patients’ survival. Moreover, neoadjuvant radiotherapy is associated with less favorable perioperative outcomes and significantly deteriorates anorectal function of patients after sphincter-preserving rectal resections.
Key words:
rectal cancer – radiotherapy – postoperative morbidity – survival – functional outcome
Zdroje
1. Herzog T, Belyaev O, Chromik AM, et al. TME quality in rectal cancer surgery. Eur J Med Res 2010;15:292−6.
2. Becker HD, et al. Karcinom rekta. In: Becker HD, et al. Chirurgická onkologie. 1. vyd. Praha, Grada Publishing 2005:505−8.
3. Hoch J, Dytrych P, Prausová J. Nádory konečníku. In: Krška Z, et al. Chirurgická onkologie. 1. vyd. Praha, Grada Publishing 2013:553−64.
4. Žaloudík J. NOT RESTING SURGEONS aneb stručný parametrický standard pro onkochirurgii. Rozhl Chir 2010;89:583−5877.
5. Ludwig K, Kosinski L. How low is low? Evolving approaches to sphincter-sparing resection techniques. Semin Radiat Oncol 2011;21:185−95.
6. Rooney P, Pranesh N. Evidence-based management of rectal cancer. In: Brown SR, et al. Contemporary coloproctology. 1. ed. London, Springer Science & Business Media 2012:173−86.
7. Påhlman L. Rectal cancer. In: Herold A, et al. Coloproctology. 1. ed. Berlin, Springer Science & Business Media 2008:213−8.
8. Leibold T, Guillem JG. The role of neoadjuvant therapy in sphincter-saving surgery for mid and distal rectal cancer. Cancer Invest 2010;28:259−67.
9. Kulu Y, Ulrich A, Büchler MW. Resectable rectal cancer: which patient does not need preoperative radiotherapy? Dig Dis 2012;30:118−25.
10. Bordeianou L, Maquire LH, Alavi K, et al. Sphincter-sparing surgery in patients with low-lying rectal cancer: techniques, oncologic outcomes, and functional results. J Gastrointest Surg 2014;18:1358−72.
11. Ceelen W, Boterberg T, Pattyn P, et al. Neoadjuvant chemoradiation versus hyperfractionated accelerated radiotherapy in locally advanced rectal cancer. Ann Surg Oncol 2007;14:424−31.
12. Foster JD, Jones EL, Falk S, et al. Timing of surgery after long-course neoadjuvant chemoradiotherapy for rectal cancer: a systematic review of the literature. Dis Colon Rectum 2013;56:921−30.
13. Garrer WY, El Hossieny HA, Gad ZS, et al. Appropriate timing of surgery after neoadjuvant chemoradiation therapy for locally advanced rectal cancer. Asian Pac J Cancer Prev 2016;17:4381−9.
14. Hawkins AT, Hunt SR. Watch and wait: is surgery always necessary for rectal cancer? Curr Treat Options Oncol 2016;17:22.
15. Sauer R, Fietkau R, Wittekind C, et al. Adjuvant vs. neoadjuvant radiochemotherapy for locally advanced rectal cancer: the German trial CAO/ARO/AIO‐94. Colorectal Dis 2003;5:406−15.
16. Rahbari NN, Elbers H, Askoxylakis V, et al. Neoadjuvant radiotherapy for rectal cancer: meta-analysis of randomized controlled trials. Ann Surg Oncol 2013;20:4169−82.
17. Berkel AE, Woutersen DP, van der Palen J, et al. Prognostic factors for postoperative morbidity and tumour response after neoadjuvant chemoradiation followed by resection for rectal cancer. J Gastrointest Surg 2014;18:1648−57.
18. Pucciarelli S, Del Bianco P, Efficace F, et al. Health-related quality of life, faecal continence and bowel function in rectal cancer patients after chemoradiotherapy followed by radical surgery. Support Care Cancer 2010;18:601−8.
19. Stelzmueller I, Zitt M, Aigner F, et al. Postoperative morbidity following chemoradiation for locally advanced low rectal cancer. J Gastrointest Surg 2009;13:657−67.
20. Wong RK, Tandan V, De Silva S, et al. Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma. Cochrane Database Syst Rev 2007:CD002102.
21. Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006;355:1114−23.
22. Denoya P, Wang H, Sands D, et al. Short-term outcomes of laparoscopic total mesorectal excision following neoadjuvant chemoradiotherapy. Surg Endosc 2010;24:933−8.
23. Kang SB, Park JW, Jeong SY, et al. Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): short-term outcomes of an open-label randomised controlled trial. Lancet Oncol 2010;11:637−45.
24. Marijnen CA, Kapiteijn E, van de Velde CJ, et al. Acute side effects and complications after short-term preoperative radiotherapy combined with total mesorectal excision in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol 2002;20:817−25.
25. Denost Q, Laurent C, Paumet T, et al. Laparoscopic surgery for rectal cancer: preoperative radiochemotherapy versus surgery alone. Surg Endosc 2012; 26:1878−83.
26. Swellengrebel HA, Marijnen CA, Verwaal VJ, et al. Toxicity and complications of preoperative chemoradiotherapy for locally advanced rectal cancer. Br J Surg 2011;98:418−26.
27. Tulchinsky H, Shmueli E, Figer A, et al. An interval >7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease–free survival in patients with locally advanced rectal cancer. Ann Surg Oncol 2008;15:2661−7.
28. Gérard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006;24:4620−5.
29. Wolthuis AM, Penninckx F, Haustermans K, et al. Impact of interval between neoadjuvant chemoradiotherapy and TME for locally advanced rectal cancer on pathologic response and oncologic outcome. Ann Surg Oncol 2012;19:2833−41.
30. Canda AE, Terzi C, Gorken IB, et al. Effects of preoperative chemoradiotherapy on anal sphincter functions and quality of life in rectal cancer patients. Int J Colorectal Dis 2010;25:197−204.
31. Kulu Y, Tarantino I, Billeter AT, et al. Comparative outcomes of neoadjuvant treatment prior to total mesorectal excision and total mesorectal excision alone in selected stage II/III low and mid rectal cancer. Ann Surg Oncol 2016;23:106−13.
32. van Gijn W, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 2011;12:575−82.
33. Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 2009;373:811−20.
34. Bruheim K, Guren MG, Skovlund E, et al. Late side effects and quality of life after radiotherapy for rectal cancer. Int J Rad Oncol Biol Phys 2010;76:1005−11.
35. Gervaz P, Rotholtz N, Pisano M, et al. Quantitative short-term study of anal sphincter function after chemoradiation for rectal cancer. Arch Surg 2001;136:192−6.
36. Kocián P, Hoch J. Funkční poruchy po resekci rekta. Rozhl Chir 2015;94:96−102.
37. Pollack J, Holm T, Cedermark B, et al. Long-term effect of preoperative radiation therapy on anorectal function. Dis Colon Rectum 2006;49:345−52.
38. Lundby L, Krogh K, Jensen VJ, et al. Long-term anorectal dysfunction after postoperative radiotherapy for rectal cancer. Dis Colon Rectum 2005;48:1343−52.
39. Peeters KC, van de Velde CJ, Leer JW, et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients - a Dutch colorectal cancer group study. J Clin Oncol 2005;23:6199−206.
40. Dahlberg M, Glimelius B, Graf W, Påhlman L. Preoperative irradiation affects functional results after surgery for rectal cancer. Dis Colon Rectum 1998;41:543−9.
41. Ziv Y, Zbar A, Bar-Shavit Y, et al. Low anterior resection syndrome (LARS): cause and effect and reconstructive considerations. Tech Coloproctol 2013;17:151−62.
42. Lange MM, den Dulk M, Bossema ER, et al. Risk factors for faecal incontinence after rectal cancer treatment. Br J Surg 2007;94:1278−84.
43. Stephens RJ, Thompson LC, Quirke P, et al. Impact of short-course preoperative radiotherapy for rectal cancer on patients´ quality of life: data from the Medical Research Council CR07/National Cancer Institute of Canada Clinical Trials Group C016 randomized clinical trial. J Clin Oncol 2010;28:4233−9.
44. Bujko K, Kepka L, Michalski W, et al. Does rectal cancer shrinkage induced by preoperative radio (chemo) therapy increase the likelihood of anterior resection? A systematic review of randomised trials. Radiothe Oncol 2006;80:4−12.
45. McCarthy K, Pearson K, Fulton R, et al. Pre-operative chemoradiation for non-metastatic locally advanced rectal cancer. Cochrane Database Syst Rev 2012:CD008368.
46. Ryska O. Přednáška profesora M. W. Büchlera v Praze. Rozhl Chir 2015; 94:139−140.
Štítky
Surgery Orthopaedics Trauma surgeryČlánok vyšiel v časopise
Perspectives in Surgery
2018 Číslo 4
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Metamizole in perioperative treatment in children under 14 years – results of a questionnaire survey from practice
Najčítanejšie v tomto čísle
- Surgical treatment of midshaft clavicular fractures using intramedullary nail
- Artificial bowel sphincter ten years later
- Liver surgery for colorectal liver metastases
- Radiotherapy in the treatment of rectal cancer − is it time to move on?